Verrica posted $12.7M in revenue for Q2 2025, up sharply from the prior year, and reported net income of $0.2M. Revenue was driven by continued growth of YCANTH and an $8M milestone from Torii. The company is advancing VP-315 into Phase 3 and expects a regulatory decision on YCANTH in Japan by year-end.

Verrica Pharmaceuticals reported Q4 2024 revenue of $0.3 million, reflecting a decline due to distributor inventory adjustments. The company reported a net loss of $16.2 million, or ($0.24) per share. Operating expenses were significantly reduced following restructuring, helping to control costs. The company expects continued revenue growth in 2025 as demand for YCANTH increases and its pipeline progresses.

Verrica Pharmaceuticals reported negative net product revenue of $1.9 million for Q3 2024, including a provision for product returns of $1.7 million. There were no ex-factory sales in the third quarter of 2024 due to slower demand pull through. The company is implementing restructuring efforts to reduce operating expenses by approximately 50% and is exploring strategies to strengthen its balance sheet. New senior leadership appointments were announced, including Dr. Jayson Rieger as CEO and John Kirby as Interim CFO.

Verrica Pharmaceuticals reported a net product revenue of $4.9 million in the second quarter of 2024, driven by YCANTH sales. The company is progressing with its clinical pipeline, including positive Phase 2 results for VP-315 and preparations for a Phase 3 trial for common warts. Net loss for the quarter was $17.2 million, or $0.37 per share.

Verrica Pharmaceuticals reported first quarter 2024 financial results, highlighting YCANTH® revenue of $3.2 million and collaboration revenue of $0.6 million. The company also received a permanent J-Code from CMS and secured new chemical entity status from the FDA for YCANTH.

Verrica Pharmaceuticals reported a net loss of $24.6 million for the fourth quarter of 2023, with product revenue of $1.9 million from YCANTH™ and $0.1 million in collaboration revenues. The company is focused on accelerating the YCANTH™ launch and advancing its pipeline, including a Phase 3 clinical trial for common warts and the completion of enrollment in a Phase 2 study for basal cell carcinoma.

Verrica Pharmaceuticals reported third quarter 2023 financial results, highlighting the first commercial sale of YCANTH™ to its exclusive distributor, FFF Enterprises Inc., resulting in net product revenue of $2.8 million. The company is focused on executing its launch strategy and expanding coverage among commercial plans and managed Medicaid plans.

Verrica Pharmaceuticals reported its Q2 2023 financial results, highlighted by the FDA approval of YCANTH™ for molluscum treatment and a $125 million debt facility to support its launch. The company's cash runway has been extended into the first quarter of 2025.

Verrica Pharmaceuticals reported collaboration revenues of $37,000 for the first quarter of 2023. The company's net loss on a GAAP basis was $6.6 million, or $0.15 per share. As of March 31, 2023, Verrica had cash and cash equivalents of $60.0 million.

Verrica Pharmaceuticals reported collaboration revenues of $0.1 million and a net loss of $5.9 million for the fourth quarter of 2022. The company's research and development expenses were $3.0 million, while general and administrative expenses totaled $3.2 million. As of December 31, 2022, Verrica had cash and cash equivalents of $34.3 million.

Verrica Pharmaceuticals reported a net income of $83 thousand for the third quarter of 2022, a significant improvement compared to the net loss of $12.8 million for the same period in 2021. The company also achieved progress in the transfer of bulk material production to Piramal Pharma Solutions and is on track to resubmit the NDA for VP-102 in Q1 2023.

Verrica Pharmaceuticals reported Q2 2022 financial results, featuring license revenues of $0.2 million. The company experienced a net loss of $10.2 million, or $0.37 per share. Verrica is preparing to resubmit its NDA for VP-102 in Q1 2023 and had cash, cash equivalents, marketable securities and restricted cash of $54.4 million as of June 30, 2022.

Verrica Pharmaceuticals reported license revenues of $0.4 million and a net loss of $8.5 million, or $0.31 per share, for the first quarter of 2022. The company's cash, cash equivalents, marketable securities, and restricted cash totaled $61.9 million as of March 31, 2022.

Verrica Pharmaceuticals reported a net loss of $9.5 million for Q4 2021, compared to a $13.0 million loss for the same period in 2020. The company is preparing for the potential launch of VP-102 for molluscum and advancing LTX-315 for non-melanoma skin cancers.

Verrica Pharmaceuticals reported a net loss of $12.8 million for the third quarter of 2021. The company is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum and expects to initiate a Phase 2 trial in basal cell carcinoma in the first quarter of 2022 for LTX-315.

Verrica Pharmaceuticals reported a net loss of $11.8 million, or $0.43 per share, for the second quarter of 2021, compared to a net loss of $9.4 million, or $0.38 per share, for the same period in 2020. The company's research and development expenses were $3.4 million, while general and administrative expenses were $7.3 million. Verrica is preparing for the potential FDA approval and commercial launch of VP-102.

Verrica Pharmaceuticals reported a net loss of $0.9 million for Q1 2021, or a loss of $0.04 per share. The company recognized $12.0 million in license revenues related to the Torii Agreement and raised approximately $30 million in an underwritten public offering. They ended the quarter with $87.7 million in cash, cash equivalents, and marketable securities.

Verrica Pharmaceuticals reported a net loss of $13.0 million for the fourth quarter of 2020. The company's NDA for VP-102 was accepted for filing by the FDA, and Torii Pharmaceutical exercised its option to acquire an exclusive license for VP-102 in Japan.

Verrica Pharmaceuticals reported a net loss of $10.5 million for the third quarter of 2020. The company is preparing to resubmit its New Drug Application (NDA) for VP-102 in the first quarter of 2021.

Verrica Pharmaceuticals reported a net loss of $9.4 million for the second quarter of 2020. The company is focusing on resubmitting the New Drug Application for VP-102 and strengthened its leadership team. They also entered into an option agreement with Torii Pharmaceutical for VP-102 in Japan.

Verrica Pharmaceuticals reported a net loss of $9.8 million for the first quarter of 2020, compared to a $7.5 million net loss for the same period in 2019. The company secured $55 million in non-dilutive loan facilities and continues to prepare for potential U.S. approval of VP-102.

Verrica Pharmaceuticals reported a net loss of $7.6 million for the fourth quarter of 2019. The FDA accepted the New Drug Application for VP-102, with a PDUFA goal date of July 13, 2020. The company also secured $55 million in non-dilutive loan facilities.